Malaria’s Effects: Symptoms, Complications, and Aftermath

Malaria does far more than cause a high fever. The disease kills hundreds of thousands of people each year, but even among survivors, it can leave a trail of organ damage, cognitive impairment, chronic anemia, and immune disruption that persists long after the parasites are cleared from the blood. The range of complications stretches from the brain to the kidneys to the placenta, and some species of the malaria parasite can hide in the liver for months or years, reigniting illness when you least expect it. Understanding the full spectrum of what malaria does to the body reveals why this ancient disease remains one of the most consequential infections on the planet.

The Fever Cycle and How Symptoms Begin

Malaria’s hallmark is a cyclical fever that spikes and breaks at somewhat predictable intervals. This pattern is not random. Each wave of fever corresponds to the synchronized rupture of infected red blood cells, which releases a new generation of parasites and triggers a flood of inflammatory signals throughout the body.¹ The timing of these cycles varies by species, but the experience for the patient is similar: shaking chills followed by a drenching fever, then profuse sweating as the temperature drops. Between these episodes, a person may feel deceptively well.

Early symptoms often mimic the flu, with headache, muscle aches, fatigue, and nausea appearing before the classic fever pattern establishes itself. This overlap with common illnesses is one reason malaria is sometimes misdiagnosed in non-endemic countries, where clinicians may not immediately think of it. In young children and pregnant women, the presentation can be even less typical, with vomiting, diarrhea, or respiratory symptoms dominating the early picture.

Why the Parasite Species Matters

Five species of Plasmodium infect humans, and they do not all behave the same way. Differences in their life cycles influence how severe the illness becomes, which organs take the heaviest hit, and how the disease responds to treatment.² P. falciparum is the deadliest and most studied, responsible for the vast majority of severe cases and deaths worldwide. It multiplies rapidly in the blood and has a unique ability to make infected red blood cells stick to the walls of small blood vessels, which is the root cause of many of its most dangerous complications.

P. vivax was long considered relatively benign, but that reputation is outdated. A prospective study comparing three species in Malaysia found that severe disease occurred in about 16% of vivax patients, not dramatically lower than the 11% rate seen with falciparum in that cohort. P. knowlesi, a species that jumps from macaque monkeys to humans in Southeast Asia, proved even more dangerous: roughly 29% of knowlesi patients developed severe malaria, with nearly a threefold greater risk of severity compared to falciparum after adjusting for other factors.³ These numbers challenged the long-held assumption that only falciparum malaria poses a serious threat to life.

Cerebral Malaria

Among the most feared complications is cerebral malaria, a condition in which the brain becomes directly involved. Infected red blood cells, along with platelets and immune cells, accumulate in the tiny blood vessels of the brain. This clogging, combined with inflammation and damage to the vessel walls, obstructs blood flow and deprives brain tissue of oxygen.⁴ The result can be seizures, coma, and death if treatment is not started quickly.

Even when children survive cerebral malaria, the damage does not always resolve. Roughly one in four child survivors develops long-term cognitive impairment, affecting memory, attention, and learning ability.⁵ Research tracking young children after cerebral malaria has found that a blood marker of brain injury, plasma tau, measured at the time of admission correlates with worse cognition over subsequent years, with particular deficits in attention and working memory.⁶ For families in endemic regions, this means a single severe malaria episode during early childhood can alter a child’s developmental trajectory for years.

Severe Anemia and Its Cascading Effects

Malaria destroys red blood cells on a massive scale, but the anemia it causes is not simply a matter of the parasite bursting the cells it infects. Uninfected red blood cells are also removed at an accelerated rate, and the bone marrow’s ability to produce replacements is suppressed. This combination of increased destruction and decreased production makes severe malarial anemia particularly difficult for the body to correct on its own.⁷ In falciparum malaria, severe anemia accounts for roughly a third of malaria-associated deaths.

The danger does not end at hospital discharge. A systematic review and meta-analysis of African children found that mortality in the six months after leaving the hospital was actually higher than the in-hospital death rate for those admitted with severe anemia. These children faced more than double the risk of dying compared to children who had been admitted for other conditions.⁸ This post-discharge vulnerability, often overlooked, highlights that surviving a hospital stay for severe malaria is only part of the battle.

Kidney, Lung, and Metabolic Complications

Malaria can injure the kidneys through several routes. In the most dramatic scenario, known as blackwater fever, massive destruction of red blood cells releases large amounts of hemoglobin into the blood, which is filtered through the kidneys and can directly damage the tubules that form urine. The resulting oxidative stress and inflammation can lead to acute kidney injury.⁹ Kidney failure was also one of the common severity markers seen in the knowlesi malaria study mentioned earlier, appearing alongside jaundice and respiratory distress as a frequent complication.

Lung involvement in malaria can progress to acute respiratory distress syndrome, or ARDS, a life-threatening condition in which the lungs fill with fluid and cannot exchange oxygen effectively. The mechanism in malaria-related ARDS appears distinct from what happens in other infections: it is driven more by immune cells called mononuclear cells than by the neutrophils that dominate in typical bacterial ARDS.¹⁰ Experimental work has further implicated direct killing of the cells lining lung blood vessels by immune cells, contributing to the breakdown of the barrier between blood and air spaces.¹¹

On the metabolic side, a dangerous buildup of lactic acid in the blood is common in severe malaria and serves as one of the strongest predictors of death. The excess lactate comes from multiple sources at once: the parasites themselves produce it inside red blood cells, activated immune cells ramp up their own lactate output, and tissues starved of oxygen by blocked blood vessels switch to oxygen-free energy production that generates even more. If the liver or kidneys are already struggling, they cannot clear the lactate fast enough, and it accumulates further.¹²

Malaria in Pregnancy

Pregnancy creates a unique vulnerability. The placenta expresses a sugar molecule on its surface that one of the parasite’s proteins has evolved to latch onto, allowing infected red blood cells to accumulate in the placental tissue and avoid being filtered out by the spleen.¹³ This process, called placental malaria, can disrupt the exchange of nutrients and oxygen between mother and fetus. The consequences include fetal growth restriction and low birth weight, both of which carry their own risks of illness and death for the newborn. In first pregnancies, when the mother has no prior immune experience with this particular form of parasite adhesion, the risk is highest. Over successive pregnancies, some degree of protective immunity develops, and the burden tends to decrease.

Relapsing Malaria and Dormant Liver Stages

Two species of malaria parasite, P. vivax and P. ovale, have a trick that none of the others possess: they can form dormant stages in the liver called hypnozoites. These sleeping parasites can reactivate weeks, months, or even years after the initial infection to cause a fresh round of illness.¹⁴ Standard malaria drugs clear the parasites from the blood but cannot reach hypnozoites in the liver; only a specific class of drug, the 8-aminoquinolines, can eliminate them.¹⁵

The timing of relapses follows geographic patterns. In tropical regions, vivax tends to relapse at roughly three-week intervals if only blood-stage drugs are given. In temperate and subtropical areas, the latency period between the initial illness and the first relapse is much longer, approximately eight to ten months, likely an adaptation to survive through seasons when mosquitoes are absent. Research has shown that most infected individuals carry multiple genetic lineages of hypnozoites in their liver, but each individual relapse is typically driven by a single lineage. Over time, the number of parasite clones detected in each successive relapse decreases, suggesting the hypnozoite population gradually shrinks through immune clearance or loss of viability.¹⁶

Post-Malaria Neurological Syndrome

Some patients develop neurological symptoms after malaria has been successfully treated and the parasites are gone. This condition, called post-malaria neurological syndrome, or PMNS, typically appears days to weeks after parasite clearance and can include confusion, seizures, tremors, and psychiatric symptoms. It occurs most often after falciparum malaria. The reassuring part is that PMNS is rare and self-limiting; most patients recover fully without lasting deficits.¹⁷ The condition appears to result from an inflammatory immune response rather than direct parasite damage, which is likely why it emerges only after the infection itself has resolved.

How Malaria Reshapes the Immune System

Repeated malaria infections leave a lasting imprint on the immune system in ways that are still being untangled. In areas with intense, year-round transmission, people develop a distinctive population of immune cells called atypical memory B cells. These cells are more abundant in regions with higher transmission.¹⁸ On one hand, their frequency correlates with broader antibody responses. On the other hand, laboratory studies suggest these cells are sluggish: they show reduced signaling and weaker effector function compared to normal memory B cells, and they may actually slow the development of full protective immunity.¹⁹

This helps explain one of the puzzling features of malaria immunology: people living in endemic areas develop partial protection that reduces the severity of illness, but sterilizing immunity that prevents infection altogether almost never develops. Decades of heavy exposure are needed to build up enough protection to reliably avoid severe disease, and that protection fades if a person moves away from an endemic area for a prolonged period. The immune system gets stuck in a partly trained state, unable to fully neutralize the parasite despite encountering it again and again.

Co-Infections and Increased Vulnerability

The massive destruction of red blood cells during a malaria episode does not just cause anemia. It also compromises the immune system’s ability to fight off other infections at the same time. The hemolysis impairs several lines of defense, including the function of macrophages and neutrophils, which are front-line cells responsible for engulfing and killing bacteria.²⁰ This makes malaria patients more vulnerable to secondary bacterial infections, particularly from gram-negative bacteria that can cause sepsis.

HIV co-infection creates an especially dangerous interaction. In a study of adults in Mozambique, patients carrying both HIV and malaria had significantly more frequent respiratory distress, bleeding, jaundice, low blood sugar, kidney failure, and higher parasite counts compared to patients with malaria alone. The overall severity of their malaria was markedly worse, with significantly higher scores on standardized criteria for severe disease.²¹ In regions of sub-Saharan Africa where both infections are common, this overlap contributes meaningfully to hospital admissions and deaths.

The Spleen Under Chronic Pressure

The spleen is the organ most directly involved in filtering infected red blood cells out of circulation, and in people with repeated malaria infections, it can enlarge dramatically. In some individuals, this process becomes pathological: the immune system’s response to chronic parasite exposure triggers an abnormal state called hyperreactive malarial splenomegaly, in which the spleen grows massively and stays enlarged even between infections.²² A hugely enlarged spleen becomes fragile and vulnerable to rupture from even minor abdominal trauma, and it can worsen anemia by trapping and destroying blood cells at an excessive rate. Treatment involves long-term antimalarial drugs to reduce the immune stimulus driving the enlargement.

Malaria’s Impact on Children’s Growth

Beyond immediate illness, malaria takes a toll on physical development in children. A cohort study in Ethiopia found that children with malaria had roughly double the odds of stunting (being too short for their age) and over eight times the odds of wasting (being too thin for their height) compared to uninfected children, after adjusting for other factors.²³ A Mendelian randomization study, which used genetic variation to isolate the causal effect of malaria from confounding factors like poverty, estimated that each malaria episode increases the risk of stunting by about a third.²⁴

A prospective study in Malawi confirmed the stunting link but found the picture to be complicated: malaria incidence was associated with a higher risk of stunting and anemia, but not with consistent changes in linear growth velocity or iron status across all children.²⁵ The mechanisms likely include appetite suppression during illness, diversion of nutrients toward immune responses, and chronic inflammation that interferes with growth signaling. In communities where children face repeated malaria episodes throughout the year, the cumulative effect on growth can be substantial.

When Treatment Itself Causes Complications

Artesunate, the most important drug for treating severe malaria, saves lives but comes with a well-documented side effect: delayed hemolysis. About a week or more after treatment begins, some patients develop a new wave of red blood cell destruction unrelated to the parasite itself. This condition, called post-artesunate delayed hemolysis, or PADH, occurs because artesunate damages infected red blood cells in a way that allows them to be “pitted” of their parasites by the spleen and returned to circulation in a damaged state. These cells are then gradually cleared by the body over the following days, causing a delayed drop in hemoglobin.²⁶

In travelers treated with intravenous artesunate for severe malaria, the phenomenon has been observed in roughly a quarter of patients, and about 60% of those affected have required blood transfusions.²⁷ The hemoglobin drop typically appears around week two after treatment starts and can occasionally be severe enough to be life-threatening. Because this complication appears after the patient has been cleared of malaria and often discharged from the hospital, clinicians need to ensure adequate follow-up with blood counts for several weeks after artesunate therapy.

Malaria’s Imprint on the Human Genome

The sheer lethality of malaria over thousands of generations has left a permanent mark on human genetics. In regions where malaria has been endemic for centuries, natural selection has favored genetic variants that offer some degree of protection against severe disease, even when those variants carry costs of their own. The best known example is the sickle cell trait: carrying one copy of the sickle hemoglobin gene substantially reduces the risk of severe malaria, while inheriting two copies causes sickle cell disease. But sickle cell is only one of many such adaptations. Thalassemias, glucose-6-phosphate dehydrogenase deficiency, and certain blood group variations all appear to have been pushed to higher frequencies in human populations by malaria’s selective pressure.²⁸

These genetic responses have evolved independently across different populations on different continents, a pattern researchers describe as convergent evolution driven by infection.²⁹ The diversity of adaptations is striking: some alter the red blood cell’s structure, others change how the immune system recognizes infected cells, and still others modify inflammatory responses. No single genetic change provides complete protection, but each shaves off enough risk to be favored by natural selection in environments where malaria exposure is intense and lifelong. The practical consequence today is that millions of people carry hemoglobin disorders and enzyme deficiencies that are, in evolutionary terms, the price of surviving malaria.